Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs

Postgraduate Medicine

Volumn 124, Issue 1, 2012, Pages 124-132

  Bron, Morgan ^a   Marynchenko, Maryna ^b   Yang, Hongbo ^b   Yu, Andrew P ^b   Wu, Eric Q ^b  

^a Takeda Pharmaceuticals International Inc   (United States)

^b ANALYSIS GROUP   (United States)

Author keywords

Health care cost; Hypoglycemia; Oral antidiabetic drug; Treatment discontinuation; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; INSULIN; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; AGE; ARTICLE; COMORBIDITY; DRUG WITHDRAWAL; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH MAINTENANCE ORGANIZATION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OVERACTIVE BLADDER; PREFERRED PROVIDER ORGANIZATION; RETROSPECTIVE STUDY; RISK FACTOR; UNITED STATES;

ADMINISTRATION, ORAL; ADULT; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SULFONYLUREA COMPOUNDS;

EID: 84863166647     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.01.2525     Document Type: Article

References (25)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2011. http://www.cdc.gov/diabetes/pubs/factsheet11.htm. Accessed February 14, 2011
2. International Diabetes Foundation. "Diabetes Atlas" Web site. 2010. http://www.diabetesatlas.org. Accessed February 14, 2010.
3. American Diabetes Association. "Diabetes Basics" Web site. 2010. http://www.diabetes.org/diabetes-basics. Accessed February 14, 2010.
4. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540-559.
5. Pratley RE, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin. 2007;23(4): 919-931.
6. Zarowitz BJ, Conner C. The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus. Pharmacotherapy. 2009;29(12 pt 2):55S-67S.
7. Amiel SA, Dixon SA, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med. 2008;25(3):245-254.
8. Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009;94(3):709-728.
9. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50(6):1140-1147.
10. Guisasola F, Povedano S, Krishnarajah G, et al. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab. 2008; 10(suppl 1):25-32.
11. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24): 2545-2559.
12. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909.
13. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301(15):1565-1572.
14. Pollack MF, Purayidathil FW, Bolge SC, Williams SA. Patient-reported tolerability issues with oral antidiabetic agents: association with adherence; treatment satisfaction and health-related quality of life. Diabetes Res Clin Pract. 2010;87(2):204-210.
15. Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care. 2008;14(2):71-75.
16. Ginde AA, Espinola JA, Camargo CA Jr. Trends and disparities in U.S. emergency department visits for hypoglycemia, 1993-2005. Diabetes Care. 2008;31(3):511-513.
17. Hammer M, Lammert M, Mejías SM, et al. Costs of managing severe hypoglycaemia in three European countries. J Med Econ. 2009;12(4): 281-290.
18. Fabunmi R, Nielsen L, Quimbo R, et al. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin. 2009;25(3):777-786.
19. Cobden D, Lee W, Balu S, et al. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy. 2007; 27(7):948-962.
20. Lee W, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clinical Therapeutics. 2006;28(10): 1712-1725.
21. Bullano M, Al-Zakwani I, Fisher M, et al. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products. Curr Med Res Opin. 2005;21(2):291-298.
22. Holstein A, Plaschke A, Egberts EH. Incidence and costs of severe hypoglycemia. Diabetes Care. 2002;25(11):2109-2110.
23. Valensi P, Benroubi M, Borzi V, et al. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Int J Clin Pract. 2009;63(3):322-531.
24. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
25. Skyler JS, Bergenstal R, Bonow RO, et al; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32(1):187-192.